FDA drug head Tidmarsh is put on leave, according to reportsnews2025-11-02T22:13:53+00:00November 2nd, 2025|Endpoints News|
Novo makes a play for Metsera; This week’s other big deal; Earnings in full swing; and morenews2025-11-01T10:00:55+00:00November 1st, 2025|Endpoints News|
Pfizer sues to stop Novo’s Metsera takeover attemptnews2025-10-31T20:41:12+00:00October 31st, 2025|Endpoints News|
Hawaii federal judge rules against FDA decision to maintain abortion pill restrictions news2025-10-31T19:27:00+00:00October 31st, 2025|Endpoints News|
Baby KJ researchers publish FDA interactions as agency eyes new pathwaynews2025-10-31T19:14:34+00:00October 31st, 2025|Endpoints News|
FDA commissioner says more ‘deregulatory’ action coming soonnews2025-10-31T17:33:28+00:00October 31st, 2025|Endpoints News|
Drugmakers are having frequent ‘most favored nation’ talks with White Housenews2025-10-31T15:57:39+00:00October 31st, 2025|Endpoints News|
Why are BridgeBio and Alnylam both seeing strong growth for their heart drugs?news2025-10-31T15:34:28+00:00October 31st, 2025|Endpoints News|
4DMT licenses eye gene therapy to Otsuka in Asia-Pacific; Arcus’ $250M offeringnews2025-10-31T14:45:46+00:00October 31st, 2025|Endpoints News|
What would Metsera bring to Novo Nordisk?news2025-10-31T11:32:14+00:00October 31st, 2025|Endpoints News|
